Low Physical Activity and Risk of Cardiovascular and All-Cause Mortality in Renal Transplant Recipients

Dorien M. Zelle,* Eva Corpeleijn,† Ronald P. Stolk,‡ Mathieu H.G. de Greef,* Rijk O.B. Gans,§ Jaap J. Homan van der Heide,* Gerjan Navis,* and Stephan J.L. Bakker§

Introduction
The incidence and prevalence of cardiovascular disease (CVD) are estimated to be four to six times higher in renal transplant recipients (RTRs) than in the general population (1,2). Classical CVD risk factors such as dyslipidemia, hypertension, and obesity, which commonly coexist as the metabolic syndrome (MS), contribute to this excess in CVD (3,4). Other factors more specific for transplantation, such as use of immunosuppressive drugs and muscle wasting, might also be relevant to this high-risk profile. However, the influence of physical activity (PA) on CVD and mortality is largely unexplored.

In the general population, PA is associated with a lower prevalence and incidence of cardiovascular (CV) risk factors, including hypertension, type 2 diabetes mellitus, obesity, and dyslipidemia (5,6). It has also been established that low PA predicts CVD and mortality in the general population (5,7,8).

In advanced chronic kidney disease (CKD), PA levels are low and remain low after renal transplantation (9,10). Most RTRs enhance their level of PA slightly immediately after transplantation, although compared with the general population, cardiorespiratory fitness in RTRs remains low (11). These low levels of PA can be explained by several factors. Muscle strength is impaired in RTRs compared with controls (10). Use of corticosteroids as immunosuppressive therapy and impaired renal function may contribute to an altered body composition, characterized by higher fat and lower muscle mass (12). Additionally, disuse of muscle by lack of PA can result in muscle atrophy (13), which is a risk factor for mortality in both RTRs and the general population (12,14).

It is not known whether low levels of PA are related to risk factors for CVD in RTRs. Likewise, it is not known whether low PA in RTRs translates into increased risk for CV and all-cause mortality.

We aimed to study cross-sectionally whether PA level is associated with CV risk factors and MS in RTRs. We further aimed to prospectively investigate in these patients whether PA is associated with CV and all-cause mortality. Finally, we sought to analyze whether these associations are independent of muscle level.
mass as apparent from 24-hour urinary creatinine excretion.

Materials and Methods

Design and Subjects

In this prospective cohort study, all RTRs who visited the outpatient clinic at the University Medical Centre Groningen between August 2001 and July 2003 were invited to participate. Eligible for participation were all adult RTRs with transplant duration >1 year and with functioning allograft at time of invitation. The group that did sign informed consent was comparable with the group that did not sign informed consent with respect to age, gender, body mass index, serum creatinine, creatinine clearance, and proteinuria. In patients with fever or other signs of infection (e.g., complaints of upper respiratory tract infection or urinary tract infection), baseline visits were postponed until symptoms had resolved. Patients with overt congestive heart failure and patients diagnosed with cancer other than cured skin cancer were not considered eligible for the study. Data on PA were available in 547 patients; 7 patients with amputations were excluded because of the possible incapability of being physically active. Full details on the study design have been previously reported (15). The Institutional Review Board approved the study protocol (METc 2001/039).

Endpoints of the study

The primary endpoints of the study were recipient CV and all-cause mortality. The continuous surveillance system of the outpatient program ensures up-to-date information on patient status and cause of death. CV and all-cause mortality was recorded until August 2007. We contacted general practitioners or referring nephrologists in case the status of a patient was unknown. Cause of death was obtained by linking the number of the death certificate to the primary cause of death as coded by a physician from the Central Bureau of Statistics. Causes of death were coded according to the International Classification of Diseases, 9th revision (ICD-9) (16). CV death was defined as deaths in which the principal cause of death was cardiovascular in nature, using ICD-9 codes 410 to 447.

Renal Transplant Characteristics

The Groningen Renal Transplant Database contains information about all renal transplants that have been performed at the University Medical Centre Groningen since 1986, including dialysis history. Relevant transplant characteristics, such as age and gender, were taken from this database. Current medication was extracted from the medical record. Presence of amputations, smoking status, and CVD history were obtained using a self-report questionnaire. CVD history was considered positive if participants had a myocardial infarction, transient ischemic attack, or cerebrovascular accident.

PA

PA data were estimated using the Tecumseh Occupational Activity Questionnaire (TOAQ) and the Minnesota Leisure Time Physical Activity Questionnaire (MLTPAQ). These questionnaires, taken by interview with trained research assistants, estimate the total amount of PA over the past 12 months. The TOAQ measures frequency, intensity, and duration of a maximum of three occupation-related activities within the previous 12 months. PAs associated with transportation to work are also included. The TOAQ is an acceptable measure of occupational PA energy expenditure and has been widely used (17). The MLTPAQ measures leisure time physical activities, including household activities, over the previous 12 months. Both questionnaires have been extensively validated against the Caltrac accelerometer, a PA record, and the doubly labeled water method (18,19).

A combination of these two questionnaires was used to estimate PA levels by using metabolic equivalents of task (MET) (20,21). These questionnaires can be combined because they measure both intensity and duration of the activity, which allows calculation summary scores in MET-minutes per day (MET-min/d). MET-minutes are calculated by multiplying the intensity (indicated by the MET-score) and the duration spent on that activity (measured in minutes). The MET-score can be derived from tables (the Compendium of Physical Activities) (22) that indicate the intensity of the activity relative to resting. MET-minutes spent on PA refer to the energy that is spend on activities, over and above existing levels of resting energy expenditure. Thus, if no notable PA is performed, PA will be scored as 0 MET-min/d. This does not imply that there is no energy expenditure, because resting energy expenditure is not taken into account in the calculation of PA. The combination of these questionnaires covers the whole of physical activities during the day. A MET is a multiple of daytime resting energy expenditure expressed in multiples of 3.5 ml O2/kg per minute consumed, approximately equaling the energy expenditure of an average adult at rest, sitting quietly in a chair (18,22). For example, 1 MET is the rate of energy expenditure while at rest, whereas normal walking corresponds to a MET-score of 3.5 and brisk walking to a MET-score of 5. If one would perform 1 hour of brisk walking per day as a single activity, the total MET-min/d for PA would be 60 × 5 = 300 MET-min/d. This means that during 1 hour of brisk walking, five times more energy is spent than during 1 hour of resting.

In addition, it was assessed how many RTRs fulfilled the most recent PA guideline (23). According to this guideline, adults should do 2.5 h/wk of moderate-intensity PA, which equals 30 minutes of moderate PA per day, for 5 d/wk. Because moderate PA corresponds to a MET-score of 3.5 (brisk walking or mid-tempo cycling are typical examples), the guidelines correspond to 30 × 5 = 150 MET-min/d for 5 d/wk.

Measurements and Definitions

Body mass index was determined as a measure of overall obesity. Waist circumference was measured on bare skin midway between the iliac crest and the 10th rib. Muscle mass was estimated by 24-hour urinary creatinine excretion as described earlier (14). Twenty-four-hour urinary creatinine excretion is considered a reliable measure of muscle mass even in patients with advanced renal failure, in elderly people, and in patients with wasting conditions (24–26). Blood was drawn after an overnight fasting
period, which included no intake of medication, including anti-hypertensive drugs and blood glucose-lowering medication. BP was measured after a 6-minute rest in supine position as the average of three automated measurements at 1-minute intervals (Omron M4; Omron Europe).

Total cholesterol was determined using the cholesterol oxidase-phenol aminophenazone method (MEGA AU 510; Merck Diagnostica, Darmstadt, Germany), and serum triglycerides were determined with the glycerol-3-phosphate oxidase-phenol aminophenazone method. HDL-cholesterol was determined with the cholesterol oxidase-phenol aminophenazone method on a Technikon RA-1000 (Bayer Diagnostics, Mijdrecht, The Netherlands), and LDL-cholesterol was calculated using the Friedewald formula (21). Plasma glucose was determined by the glucose-oxidase method (YSI 2300 Stat plus; Yellow Springs). Serum high sensitive C-reactive protein (hsCRP) was assessed with a high sensitivity CRP ELISA assay. Serum and urine creatinine concentration were analyzed with a photometric modification with the Jaffé method. Creatinine clearance was calculated from 24-hour urinary creatinine excretion and serum creatinine. Total urinary protein concentration was analyzed using the Biuret reaction (MEGA AU 510; Merck Diagnostica), and proteinuria was defined as urinary protein excretion >0.5 g/24 h.

In this study, MS was defined by the definition of the National Cholesterol Education Program Expert Panel (27). Recently, the American Diabetes Association (ADA) lowered the cut-off point for impaired fasting glucose to ≥5.6 mmol/L (28). For our analysis of the prevalence of MS, we used this ADA cut-off point. Diabetes was defined according to the guidelines of the ADA as a fasting plasma glucose ≥7.0 mmol/L or the use of anti-diabetic medication (29).

Statistical Analyses
Data were analyzed with SPSS version 16.0 (SPSS, Chicago, IL) and GraphPad Prism version 4.03 (GraphPad Software, San Diego, CA). Normally distributed variables are expressed as mean ± SD, whereas skewed distributed variables are given as median (25th to 75th percentile); percentages were used to summarize categorical variables. Log transformation was used for variables with a skewed distribution. Hazard ratios are reported with 95% confidence interval.

Recipient-related characteristics were analyzed separately for tertiles of PA level; predicted values are shown adjusted for age. ANOVA or Kruskal-Wallis test was used to compare means for continuous variables, with χ² for categorical variables. To analyze whether PA is associated with mortality, we first performed a Kaplan-Meier analyses with a log-rank test.

Multivariate Cox regression analyses were performed to study whether PA is independently associated with CV and all-cause mortality. For these analyses MET-minutes per day were first log transformed to achieve a normal distribution and entered in the model as a continuous variable. In multivariate Cox regression analyses, we first adjusted for recipient age, gender (model 2), and history of CV events (model 3). In addition to the adjustments for age, gender, and history of CV events, we performed adjustment for insulin concentration, systolic BP, waist circumference, triglycerides, smoking, and hsCRP (model 4). Similarly, we adjusted for Framingham risk score factors (model 5), creatinine clearance and urinary protein excretion (model 6), and 24-hour urinary creatinine excretion (model 7). We also studied potential interactions between PA and 24-hour urinary creatinine excretion as a measure for muscle mass.

Results
A total of 540 RTRs were studied (mean age, 51 ± 12 years; 54% men). Baseline characteristics according to gender-stratified tertiles of PA of the RTRs are shown in Table 1. Because PA was strongly inversely associated with age, we also adjusted the gender-stratified baseline characteristics for age.

During follow-up for 5.3 [4.7 to 5.7] years, 81 recipients died, with 37 deaths being CV in origin. Incidence of CV death significantly decreased according to increasing tertiles of PA, with respective numbers of 21 (11.7%), 13 (7.2%), and 3 (1.7%) (P < 0.001; Figure 1A). A similar association was present for all-cause mortality, with numbers of 50 (27.8%), 39 (21.7%), and 30 (16.7%) according to increasing tertiles, respectively (P < 0.001; Figure 1B). RTRs with moderate PA levels (second tertile) already had a lower risk for CV and all-cause mortality than inactive RTRs (first tertile).

Results of univariate and multivariate Cox regression analyses for associations of PA as a log-transformed continuous variable with CV and all-cause mortality are presented in Table 2. In univariate analyses, low PA strongly predicted CV and all-cause mortality in RTRs (model 1). These associations slightly weakened after adjustment for age and gender (model 2). The same was true for adjustment for history of CVD (model 3) and components of MS, smoking, fasting insulin concentration, and hsCRP (model 4). In model 5, adjustments were made for Framingham risk score factors (model 3) and components of MS, smoking, fasting insulin concentration, and hsCRP (model 4). In model 5, adjustments were made for Framingham risk score factors (model 3) and components of MS, smoking, fasting insulin concentration, and hsCRP (model 4). In model 5, adjustments were made for Framingham risk score factors (model 3) and components of MS, smoking, fasting insulin concentration, and hsCRP (model 4).
RTRs, results of univariate and multivariate analyses remained materially unchanged.

In multivariate Cox regression analyses, no interaction between urinary creatinine excretion and PA was found.

**Discussion**

This study showed that low PA levels are strongly associated with CV and all-cause mortality in RTRs. To our knowledge, this is the first study to report on PA level and CV and all-cause mortality in these patients. This is consistent with earlier findings in dialysis, CKD, and the general population (8,9,31). Furthermore, it shows low levels of PA are positively associated with CVD risk factors in RTRs. Independent of age, PA was inversely associated with history of CVD, presence of MS, fasting insulin concentration, and triglycerides, and positively associated with kidney function and 24-hour urinary creatinine excretion (as a measure of muscle mass).

We anticipated that a potential association of PA with mortality could depend on risk factors for CVD, MS, or smoking status. We found, however, that the association of PA with mortality was not substantially affected by adjustments for history of CV events, insulin concentrations, components of the MS, or Framingham risk score factors. The same holds for adjustments for renal function, despite differences in creatinine clearance over the tertiles. Another anticipated confounder was the effect of muscle mass, as reflected by 24-hour creatinine excretion, on the association between PA and mortality. In a previous study, we showed that muscle mass (as measured by 24-hour creatinine excretion) is associated with mortality in RTRs (12). Therefore, we speculated that low PA is associated with low muscle mass and thereby with higher mortality. Indeed, we now found that RTRs with higher PA also had higher 24-hour creatinine excretion (i.e., larger muscle mass). However, on multivariate analyses, PA was associated with CV and all-cause mortality independent of 24-hour creatinine excretion. Based on the association between PA and mortality, it is tempting to speculate that improvement of PA levels could contribute to improved survival in RTRs.

PA may modulate CVD risk in several ways. Several clinical studies in the general population showed that PA lowers BP (32), improves body composition (33), lowers triglycerides (34), and improves glucose tolerance and insulin sensitivity (35,36). PA could modulate components of

---

**Table 1. Baseline characteristics according to tertiles of physical activity**

<table>
<thead>
<tr>
<th>Tertiles of Physical Activitya</th>
<th>Inactive (n = 180)</th>
<th>Moderate (n = 180)</th>
<th>Active (n = 180)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>General characteristics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>age (years)</td>
<td>56.1 ± 11.0</td>
<td>51.6 ± 11.8</td>
<td>46.0 ± 11.5</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>smoking, n (%)</td>
<td>48 (26)</td>
<td>33 (18)</td>
<td>38 (21)</td>
<td>0.2</td>
</tr>
<tr>
<td>MS, n (%)</td>
<td>135 (75)</td>
<td>118 (70)</td>
<td>111 (62)</td>
<td>0.007</td>
</tr>
<tr>
<td>Cardiac vascular disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>myocardial infarction, n (%)</td>
<td>21 (12)</td>
<td>13 (7)</td>
<td>9 (5)</td>
<td>0.06</td>
</tr>
<tr>
<td>transient ischemic attack/cerebrovascular accident, n (%)</td>
<td>17 (10)</td>
<td>9 (5)</td>
<td>6 (3)</td>
<td>0.05</td>
</tr>
<tr>
<td>Body composition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>body mass index (kg/m²)</td>
<td>26.3 ± 4</td>
<td>25.8 ± 4</td>
<td>26.0 ± 4</td>
<td>0.7</td>
</tr>
<tr>
<td>waist circumference in women (cm)</td>
<td>96.6 ± 14</td>
<td>93.2 ± 14</td>
<td>92.4 ± 14</td>
<td>0.1</td>
</tr>
<tr>
<td>waist circumference in men (cm)</td>
<td>100.4 ± 12</td>
<td>98.2 ± 12</td>
<td>100.3 ± 12</td>
<td>0.4</td>
</tr>
<tr>
<td>urinary creatinine excretion (mmol/24 h)</td>
<td>10.7 [10.3 to 1.2]</td>
<td>11.4 [10.9 to 1.9]</td>
<td>12.5 [11.9 to 1.3]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Blood pressure</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>systolic BP (mmHg)</td>
<td>150 ± 22</td>
<td>157 ± 22</td>
<td>151 ± 23</td>
<td>0.003</td>
</tr>
<tr>
<td>diastolic BP (mmHg)</td>
<td>89 ± 10</td>
<td>92 ± 10</td>
<td>90 ± 10</td>
<td>0.04</td>
</tr>
<tr>
<td>anti-hypertensive medication, n (%)</td>
<td>164 (91)</td>
<td>149 (83)</td>
<td>158 (88)</td>
<td>0.08</td>
</tr>
<tr>
<td>use of ACE inhibitor, n (%)</td>
<td>65 (36)</td>
<td>50 (28)</td>
<td>70 (39)</td>
<td>0.09</td>
</tr>
<tr>
<td>use of β-blocker, n (%)</td>
<td>119 (66)</td>
<td>108 (60)</td>
<td>108 (60)</td>
<td>0.5</td>
</tr>
<tr>
<td>Lipids and inflammation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>total cholesterol (mmol/L)</td>
<td>5.65 ± 1.1</td>
<td>5.59 ± 1.1</td>
<td>5.61 ± 1.1</td>
<td>0.89</td>
</tr>
<tr>
<td>HDL-cholesterol (mmol/L)</td>
<td>1.06 ± 0.34</td>
<td>1.12 ± 0.32</td>
<td>1.12 ± 0.34</td>
<td>0.13</td>
</tr>
<tr>
<td>LDL-cholesterol (mmol/L)</td>
<td>3.6 ± 1.0</td>
<td>3.5 ± 1.0</td>
<td>3.6 ± 1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>triglycerides (mmol/L)</td>
<td>2.0 [1.9 to 2.1]</td>
<td>2.0 [1.8 to 2.1]</td>
<td>1.8 [1.6 to 1.9]</td>
<td>0.05</td>
</tr>
<tr>
<td>hscTDR (mg/L)</td>
<td>2.5 [2.2 to 2.8]</td>
<td>1.9 [1.7 to 2.1]</td>
<td>1.8 [1.6 to 2.0]</td>
<td>0.05</td>
</tr>
<tr>
<td>Glucose homeostasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>glucose (mmol/L)</td>
<td>5.0 ± 1.4</td>
<td>4.8 ± 1.4</td>
<td>4.8 ± 1.4</td>
<td>0.4</td>
</tr>
<tr>
<td>insulin (µmol/L)</td>
<td>12.7 [11.7 to 13.8]</td>
<td>11.2 [10.3 to 12.1]</td>
<td>10.2 [9.4 to 11.1]</td>
<td>0.001</td>
</tr>
<tr>
<td>diabetes mellitus, n (%)</td>
<td>36 (20)</td>
<td>31 (17)</td>
<td>27 (15)</td>
<td>0.4</td>
</tr>
<tr>
<td>Renal function</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>serum creatinine (µmol/L)</td>
<td>141.6 [135 to 149]</td>
<td>137.1 [131 to 144]</td>
<td>136.5 [130 to 143]</td>
<td>0.6</td>
</tr>
<tr>
<td>creatinine clearance (ml/min)</td>
<td>53.1 [50 to 56]</td>
<td>57.8 [55 to 61]</td>
<td>63.4 [60 to 67]</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>urinary protein excretion (g/24 h)</td>
<td>0.36 [0.3 to 0.4]</td>
<td>0.35 [0.3 to 0.4]</td>
<td>0.32 [0.3 to 0.4]</td>
<td>0.8</td>
</tr>
<tr>
<td>proteinuria &gt; 0.5 g/24 h, n (%)</td>
<td>50 (28)</td>
<td>52 (29)</td>
<td>50 (28)</td>
<td>0.9</td>
</tr>
</tbody>
</table>

Data are represented as mean ± SD or median [95% confidence interval]. Differences were tested by ANOVA or Kruskal-Wallis test for continuous variables and with χ² for categorical variables. ACE inhibitor, angiotensin converting enzyme inhibitor.

*Tertiles of PA are stratified for gender and values are adjusted for age.
the MS in RTRs in the same way as in the general population, which is supported by our data. Most RTRs gain substantial weight after transplantation, mainly because of an increase in fat mass (37). Inactivity is strongly associated with obesity, and consequently, with the accumulation of visceral fat (38). Both visceral fat and physical inactivity itself are associated with the activation of inflammatory pathways (39), which in turn is involved in the cascade of

Figure 1. | (A) Kaplan-Meier curves of cardiovascular mortality according to gender-stratified tertiles of PA. *Adjusted for age (P < 0.001). (B) Kaplan-Meier curves of mortality according to gender-stratified tertiles of PA. *Adjusted for age (P < 0.001).

<table>
<thead>
<tr>
<th>Table 2. Hazard ratios for cardiovascular and all-cause mortality by PA as a log-transformed continuous variable</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Model</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>1</td>
</tr>
<tr>
<td>2</td>
</tr>
<tr>
<td>3</td>
</tr>
<tr>
<td>4</td>
</tr>
<tr>
<td>5</td>
</tr>
<tr>
<td>6</td>
</tr>
<tr>
<td>7</td>
</tr>
</tbody>
</table>

atherosclerosis and insulin resistance (40,41). The factors above could partially explain the modulating effect of PA on CVD risk.

Another mechanism that could elucidate the cardioprotective effects of exercise is vascular adaptation. Physical inactivity could lead to endothelial dysfunction in part by reduced activity of vascular nitric oxide, an established precursor to the atherosclerosis process (42,43). Exercise training has been shown to increase nitric oxide production, angiogenesis, and arteriogenesis and reduce vascular oxidative stress; this could represent the response to exercise that protects against CVD (43,44).

In our study, median energy expenditure attributable to PA was 115 MET-min/d, with values of 69 MET-min/d for women and 204 MET-min/d for men. Richardson et al. (18) measured a mean energy expenditure of about 410 MET-min/d in healthy subjects using the MLTPAQ, which only measures leisure time physical activity. Thus, compared with healthy subjects, RTRs have low PA levels in our study, which is in line with two other studies in which RTRs had lower levels of PA compared with healthy subjects (45,46). A 5-year follow-up study showed that most RTRs spontaneously became more active after transplantation, which was associated with a better quality of life (46). Although PA levels increase after transplantation, they often remain relatively low (45,47).

There could be several reasons for the low levels of PA in RTRs. Exercise capacity is approximately 30% lower in RTRs than in controls (10). The main determinants of exercise capacity in RTRs are skeletal muscle strength and PA level (47). It is difficult to determine whether low PA levels are caused by low muscle mass or the other way around. Before transplant, muscle mass is frequently low as a consequence of muscle wasting associated with ESRD and chronic hemodialysis (48). Metabolic acidosis and chronic inflammation contribute to the process of muscle protein degradation (48). After transplantation, chronic exposure to corticosteroids can contribute to decreased muscle mass. In line with this, we found in an earlier study that cumulative prednisolone dose was inversely related to muscle mass as reflected by 24-hour urinary creatinine excretion (12). Thus, a primary lack in muscle mass may impair RTRs in their capacity to exert PA. However, use of corticosteroids has been shown to not limit the potential to build muscle mass and exercise capacity (47). It has also been shown that disuse of muscle because of a lack of PA can adversely affect muscle mass (13). It is therefore obvious that to restore and maintain muscle mass after transplantation, regular PA is needed. Another reason for inactivity may also be uncertainty about being capable of being (and being allowed to be) physically active, with fear of injuring the graft playing a role in this uncertainty.

Exercise studies in RTRs have indicated that exercise training results in an improved exercise capacity, increased muscle strength, improved BP control and bone remodeling, and higher levels of self-reported physical functioning (11,47). These results show that exercise training in RTRs can be effective and feasible. Our results suggest that exercise training may benefit RTRs in terms of better survival. In regular care after transplantation, exercise training is not yet incorporated. Further research is needed to study the role of PA intervention after renal transplantation in the prevention and treatment of CV risk factors, physical functioning, and long-term outcome.

The strength of our study is its prospective design. RTRs in this study were closely monitored by regular check-up in our clinic, which allows for extensive information gathering on patient status. A limitation of our study is that we used questionnaires to measure PA. However, the questionnaires have been validated (17–19), and the RTRs were interviewed by trained research assistants. Recall bias and social desirability bias where the participants could tend to report high volumes of PA are unfortunately unavoidable and could influence internal validation. Validation studies have shown that questionnaires may be effective in classifying people into broad categories of PA (e.g., inactive, moderate, and active) but are less appropriate for quantifying absolute energy expenditure (49). Therefore, the focus in this study is not on absolute MET scores of PA but on the ranking based on these scores. It is tempting to speculate that stimulation of PA will improve outcome after transplantation. This study is, however, observational in design and not an intervention study; thus, hard conclusions on causality can not be drawn. We can not exclude a more general effect of a more healthy lifestyle, but our data support that PA contributes to a healthy lifestyle pattern in RTRs.

In summary, low PA is an independent risk factor for CV and all-cause mortality in RTRs. Our data suggest that increased PA might have a CV survival benefit for RTRs. Given the four to six times increased CV mortality in RTRs, there is great potential for mortality reduction by exercise participation in these patients.

Acknowledgments

This research was performed within the framework of CTMM, the Centre for Translational Molecular Medicine (www.ctmm.nl), project PREDICt (Grant 01C-104), and was supported by The Netherlands Heart Foundation, Dutch Diabetes Research Foundation, and Dutch Kidney Foundation.

Disclosures

None.

References

5. Leitzmann MF, Park Y, Blair A, Ballard-Barbash R, Mow T, Hollenbeck A, Schatzkin A: Physical activity recommenda-
45. van den Ham EC, Kooman JP, Christiaans MH, van Hoof JP: Relation between steroid dose, body composition and physi-
Low Physical Activity Predicts RTR Mortality, Zelle et al.

Received: April 16, 2010 Accepted: November 8, 2010

Published online ahead of print. Publication date available at www.cjasn.org.
KIDNEY TRANSPLANT RECIPIENTS: GET MOVING TO SAVE YOUR LIFE

Patients who engage in little physical activity face increased risks of dying prematurely

Washington, DC (February 25, 2011) — Low physical activity increases kidney transplant patients’ likelihood of dying early, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). The results suggest that patients need to exercise to fend off an early death.

Inactive people in general face increased risks of developing cardiovascular disease and of dying prematurely. Individuals with chronic kidney disease—particularly those on dialysis—tend to get little exercise, but most increase their activity levels modestly after receiving a kidney transplant. Until now, no one has examined whether low physical activity levels in kidney transplant recipients is associated with an increased risk of dying prematurely from heart-related or other causes. Maintaining heart health is particularly important for these individuals, as kidney transplant recipients have a 4- to 6-fold increased risk of dying from cardiovascular causes than individuals in the general population.

Dorien Zelle (University Medical Center Groningen, in the Netherlands) and her colleagues studied the health of 540 kidney transplant recipients between 2001 and 2003, assessing physical activity through questionnaires and recording deaths until August 2007. With regard to the guidelines for minimum requirements of physical activity, 260 (48%) patients did not meet the criteria and 79 (14.6%) were completely inactive.

During the study period, 81 patients died, with 37 heart-related deaths; the lower the level of physical activity, the higher the rate of deaths. Specifically, cardiovascular deaths occurred in 11.7%, 7.2%, and 1.7% of patients considered inactive, moderately active, and active, respectively. Deaths from any cause occurred at rates of 24.4%, 15.0%, and 5.6% in these respective groups.

The investigators acknowledged that in general, sicker people are less likely to exercise and more likely to die; however, they found that the link between low physical activity and premature death was not substantially affected by adjustments for factors such as patients’ heart health, kidney function, muscle mass, and their diabetes and smoking status.
Dr. Zelle noted that to determine whether increased physical activity levels may improve the health and prolong the lives of transplant recipients, the University Medical Center Groningen, in collaboration with the University Medical Center Maastricht, will start a randomized controlled lifestyle intervention study. Kidney transplant recipients will undergo a supervised exercise program and receive individual counseling to promote physical activity and a healthy diet.

Study co-authors include Eva Corpeleijn, PhD, Ronald Stolk, MD, Mathieu de Greef, PhD, Reinold Gans, MD, Gerjan Navis, MD, and Stephan Bakker MD, PhD (University Medical Center Groningen, in the Netherlands).

Disclosures: This research was performed within the framework of the Centre for Translational Molecular Medicine, project PREDICCT (Prediction and Early Diagnosis of Diabetes and Diabetes-related Cardiovascular Complications, grant 01C-104), and supported by the Netherlands Heart Foundation, Dutch Diabetes Research Foundation, and Dutch Kidney Foundation.


The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.

Founded in 1966, and with more than 12,000 members, the American Society of Nephrology (ASN) leads the fight against kidney disease by educating health professionals, sharing new knowledge, advancing research, and advocating the highest quality care for patients.

# # #